title: Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.
authors.forename: Stephen
authors.initials: S
authors.lastname: Esker
authors.forename: Jessica
authors.initials: J
authors.lastname: Albano
authors.forename: Jonathan
authors.initials: J
authors.lastname: Uy
authors.forename: Dilek
authors.initials: D
authors.lastname: Arikan
authors.forename: Maria Jesus
authors.initials: MJ
authors.lastname: Jimenez-Exposito
authors.forename: Daniel
authors.initials: D
authors.lastname: Seekins
authors.forename: Hugh
authors.initials: H
authors.lastname: Tilson
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D000069446:Atazanavir Sulfate; D003625:Data Collection / Q000706:statistics & numerical data; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D011725:Pyridines / Q000009:adverse effects*; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate